HC Wainwright Issues Positive Outlook for CATX Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Research analysts at HC Wainwright upped their Q2 2025 earnings estimates for Perspective Therapeutics in a report issued on Monday, March 31st. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.28) per share for the quarter, up from their previous forecast of ($0.29). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Perspective Therapeutics’ Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.32) EPS and FY2025 earnings at ($1.18) EPS.

A number of other equities research analysts have also issued reports on CATX. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Royal Bank of Canada decreased their price objective on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Thursday, March 27th. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. Scotiabank initiated coverage on Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price target on the stock. Finally, Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a report on Wednesday, March 26th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Perspective Therapeutics presently has a consensus rating of “Buy” and an average target price of $14.44.

Perspective Therapeutics Stock Up 4.6 %

CATX stock opened at $2.05 on Thursday. Perspective Therapeutics has a 12 month low of $1.90 and a 12 month high of $19.05. The company has a 50-day moving average price of $2.85 and a 200 day moving average price of $6.07.

Institutional Trading of Perspective Therapeutics

Large investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. lifted its position in Perspective Therapeutics by 221.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock valued at $5,788,000 after purchasing an additional 298,778 shares during the period. State Street Corp lifted its holdings in shares of Perspective Therapeutics by 119.6% in the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after buying an additional 1,192,812 shares during the period. Janus Henderson Group PLC lifted its holdings in Perspective Therapeutics by 8.0% in the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after acquiring an additional 355,685 shares during the period. FMR LLC boosted its position in Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after purchasing an additional 5,370,392 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in Perspective Therapeutics by 1,302.7% during the third quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock worth $635,000 after buying an additional 44,174 shares in the last quarter. 54.66% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Perspective Therapeutics

In other Perspective Therapeutics news, CEO Johan M. Spoor acquired 22,026 shares of the stock in a transaction dated Friday, March 28th. The stock was purchased at an average price of $2.24 per share, with a total value of $49,338.24. Following the transaction, the chief executive officer now directly owns 59,383 shares of the company’s stock, valued at $133,017.92. This trade represents a 58.96 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Juan Graham purchased 33,333 shares of the stock in a transaction on Friday, March 28th. The stock was acquired at an average cost of $2.25 per share, with a total value of $74,999.25. Following the acquisition, the chief financial officer now owns 35,354 shares of the company’s stock, valued at approximately $79,546.50. This represents a 1,649.33 % increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 115,696 shares of company stock worth $256,344 over the last three months. Corporate insiders own 3.52% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.